Inc. All rights reserved. LE-T is designed for the treatment of ocular inflammation where the risk of bacterial infection exists.
Topical corticosteroids offer the broadest range of treatment for ocular inflammation.
A Phase III clinical study of LE-T is currently underway. Technology Loteprednol etabonate is the active ingredient in Alrex and Lotemax . This new chemical entity is designed to be active at the site of application and then to hydrolyze to an inactive metabolite after achieving its therapeutic role. Tobramycin is an aminoglycoside antibiotic, with a long history of efficacy and safety used both in the eye and by other routes. Its combination with loteprednol etabonate provides the dual action of an anti-inflammatory and an antimicrobial.